Accès gratuit
Numéro
Med Sci (Paris)
Volume 18, Numéro 5, Mai 2002
Page(s) 563 - 564
Section Le Magazine : Dernière Heure
DOI http://dx.doi.org/10.1051/medsci/2002185563
Publié en ligne 15 mai 2002
  1. Brunner H, Gavras H. Commentary. Angiotensin blockade for hypertension: a promise fulfilled. Lancet 2002; 359 : 990–1.
  2. The sixth report of the joint national committe on prevention, detection evaluation and treatement of high blood pressure. Arch Intern Med 1997; 157 : 2413–46.
  3. Dahlof B, Devereux RB, Kjeldsen SE, et al.Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension (LIFE): a randomized trial against atenolol. Lancet 2002; 359 : 995–1003.
  4. Lindholm LH. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359 :1004–10.
  5. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345 : 861–9.
  6. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345 : 851–60.
  7. Parving HH. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345 : 870–8.
  8. Heart outcomes prevention evaluation (HOPE) study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudt. Lancet 2000; 355 : 253–9.